Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
Interventions: BIOLOGICAL: PERT-IJS plus trastuzumab, carboplatin and docetaxel|BIOLOGICAL: Perjeta plus trastuzumab, carboplatin and docetaxel
Sponsor: Biocon Biologics UK Ltd